|
|
|
|
|
HONG KONG, July 21, 2020 - (ACN Newswire) - Genor Biopharma Co. Inc, a pre-commercial stage biopharmaceutical company focused on developing and commercializing oncology and autoimmune therapeutics, announced that the new drug application (NDA) for Geptanolimab, a novel PD-1 mAb drug candidate, has been accepted by the National Medical Products Administration ("NMPA") for the treatment of Peripheral T cell Lymphoma (PTCL).
On the same day, Genor Biopharma announced the appointment of Mr. CHEN Wende as Chief Operation Officer. In this role, Mr. CHEN will oversee commercialization and prepare for launches of late-stage drug candidates.
Mr. CHEN brings over 20 years of experience in biopharmaceutical industry, focusing on sales and marketing and business operation at Roche, AstraZeneca, and Pfizer in China. Mr. CHEN was most recently Chief Commercial Officer at a well-known biotech company. Before that, Mr. CHEN served as Vice President at Roche China, overseeing Corporate Affairs, Market Access and Channel Management for a number of key drugs including Herceptin, MabThera, Avastin, Tarceva and Zelboraf. Mr. CHEN also served as Senior Vice President at AstraZeneca from 2010 and as Senior Sales Director at Pfizer from 2000.
"We are excited to appoint Mr. CHEN as COO of Genor Biopharma. We are looking to file NDAs for a number of our late-stage drug candidates in the near term," commented Dr. GUO, Chief Executive Officer of Genor Biopharma, "With over 20 years of experience in drug commercialization and deep insight of the landscape, Mr. CHEN will build our in-house commercialization team and lead our drug launches with differentiated strategy and drive our transformation into a biopharma company."
About JHBP (CY) Holdings Limited ("Genor Biopharma")
Established in December 2007, JHBP (CY) Holdings Limited is a biopharmaceutical powerhouse focusing on developing and commercializing oncology and autoimmune drugs. The Company has been strategically focused on major therapeutic areas with substantial unmet medical needs. At present, the Company has more than 10 drug candidates, 10 of which have entered the clinical development stage. The Company's pipeline products are mainly deployed in the field of cancer and other major diseases and have established a series of mature technology platforms in antibody drug research, development and manufacturing to serve patients in China and around the world. The Company's leadership team boasts more than 20 years of industry experience in global biopharmaceutical companies such as Pfizer, Merck, Amgen and AbbVie with proven track record and a well-balanced combination of expertise. The Company currently has around 400 employees across 3 sites in China - Shanghai Zhangjiang, Yunnan Yuxi, and Beijing office, as well as lab in South San Francisco, US, among which 80% are R&D and clinical specialists.
Topic: Press release summary
Source: Genor Biopharma
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2026 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
Latest Press Releases
Sinch Mailgun Report: Companies are Leaving Email Performance on the Table
Apr 23, 2026 09:00 HKT/SGT
|
|
|
Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance
Apr 22, 2026 22:00 HKT/SGT
|
|
|
China Gas Signs Strategic Cooperation Agreement with CITIC Construction and China CITIC Bank
Wednesday, April 22, 2026 8:32:00 PM
|
|
|
CBL International Limited Acquires Majority Stake in Green Marine Energy Holdings Limited
Wednesday, April 22, 2026 8:15:00 PM
|
|
|
GMG Appoints New Chief Production Growth Officer and Provides Update on Global Production Plans
Apr 22, 2026 19:59 HKT/SGT
|
|
|
OMRON Healthcare and Tricog Health strengthen collaboration in India with Tricog CardioCheck (TCC) 
Wednesday, April 22, 2026 6:30:00 PM
|
|
|
TMX Group Announces Agreement to Acquire Cboe Australia and Cboe Canada
Apr 22, 2026 18:29 HKT/SGT
|
|
|
Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Apr 22, 2026 18:08 HKT/SGT
|
|
|
MHI Marine Machinery & Equipment and Mitsubishi Shipbuilding Obtain Approval in Principle (AiP) for the Basic Design of a Methane Oxidation Catalyst System for Marine LNG-Fueled Engines from Classification Society ClassNK
Wednesday, April 22, 2026 4:16:00 PM
|
|
|
Luxury NEV Maker Seres Delivers Sustained Profitability and Strong Dividends
Apr 22, 2026 15:31 HKT/SGT
|
|
|
|
|
More Press release >> |
|
 |
|
|
|
|
 |
|
